Gain Therapeutics, Inc.
GANX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001819411
No open-market purchases or sales by Gain Therapeutics, Inc. insiders were filed in the last 90 days; 50 institutions reported holding it in 13F filings for Q2 2026, worth $17.4M in total; Greenlight Capital is the only superinvestor holding it.
13F holders, Q4 2021
Institutional positions in Gain Therapeutics, Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 19
- +5 vs. Q3 2021
- Shares held
- 1.06M
- +163.1K (+18.3%) vs. Q3 2021
- Total value
- $5.71M
- −$939.0K (−14.1%) vs. Q3 2021
- New holders
- 7
- 4 more added
- Sold out
- 2
- 1 more reduced
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting GANX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 50 | $17.4M |
| Q1 2026 | 42 | $15.8M |
| Q4 2025 | 48 | $25.9M |
| Q3 2025 | 38 | $7.70M |
| Q2 2025 | 35 | $6.49M |
| Q1 2025 | 33 | $5.07M |
| Q4 2024 | 25 | $3.94M |
| Q3 2024 | 19 | $2.40M |
| Q2 2024 | 28 | $3.89M |
| Q1 2024 | 26 | $7.04M |
| Q4 2023 | 24 | $5.05M |
| Q3 2023 | 24 | $4.95M |
| Q2 2023 | 24 | $5.68M |
| Q1 2023 | 22 | $5.54M |
| Q4 2022 | 21 | $3.78M |
| Q3 2022 | 23 | $3.95M |
| Q2 2022 | 16 | $3.87M |
| Q1 2022 | 16 | $4.75M |
| Q4 2021 | 19 | $5.71M |
| Q3 2021 | 14 | $6.65M |
| Q2 2021 | 14 | $8.95M |
| Q1 2021 | 12 | $15.0M |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding Gain Therapeutics, Inc.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Wells Fargo & Company | 23 | $0 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 800 | $4.00K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 1,170 | $7.00K | 0.00% | +615+110.8% | Added |
| Banque Cantonale Vaudoise | 3,000 | $16.0K | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 10,050 | $54.0K | 0.00% | +10,050 | New |
| UBS Group AG | 10,497 | $57.0K | 0.00% | +3,757+55.7% | Added |
| Royal Bank of Canada | 10,560 | $57.0K | 0.00% | +10,560 | New |
| BlackRock Inc. | 11,159 | $60.0K | 0.00% | −317−2.8% | Reduced |
| Citadel Advisors LLC | 13,029 | $70.0K | 0.00% | +13,029 | New |
| Millennium Management LLC | 15,754 | $84.0K | 0.00% | +15,754 | New |
| Susquehanna International Group, LLP | 19,357 | $103.0K | 0.00% | +19,357 | New |
| Two Sigma Investments, LP | 19,467 | $106.0K | 0.00% | +19,467 | New |
| Geode Capital Management, LLC | 20,056 | $107.0K | 0.00% | +20,056 | New |
| Veritable, L.P. | 25,064 | $136.0K | 0.00% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 50,000 | $267.0K | 0.00% | 00.0% | Unchanged |
| Prelude Capital Management, LLC | 58,100 | $315.0K | 0.02% | 00.0% | Unchanged |
| CM Management, LLC | 90,000 | $489.0K | 0.37% | +25,673+39.9% | Added |
| Telemetry Investments, L.L.C. | 151,132 | $807.0K | 1.06% | +54,900+57.0% | Added |
| Greenlight Capital Inc | 546,560 | $2.97M | 0.18% | 00.0% | Unchanged |
| Indie Asset Partners, LLC | 0 | $0 | 0.00% | −29,652−100.0% | Sold out |
| Steward Partners Investment Advisory, LLC | 0 | $0 | 0.00% | −100−100.0% | Sold out |